News
MYL
--
0.00%
--
UPDATE 2-Senate meetings on Tanden postponed, suggesting lack of support for Biden budget pick
reuters.com · 2d ago
Fitch Rtgs: Pandemic Fallout to Delay US Drug Price Reform, Biosimilars Uptake
reuters.com · 02/18 16:16
What We Know About How Moderna and Pfizer Vaccines Compare
“Efficacy is likely the same,” Raymond James analyst Steven Seedhouse surmises. A surer comparison will become possible when both trials report detailed results in medical journals.
Barrons.com · 11/16/2020 20:19
Benzinga Pro's Top 5 Stocks To Watch For Monday, Nov. 16, 2020: MRNA, WMT, MYL, NVDA, IMMR
Today's 5 Stock Ideas:  Moderna (MRNA) - Vaccine news out of the company is moving the entire stock market Monday morning. Moderna reported its COVID-19 vaccine showed 95% effectiveness. The stock was up
Benzinga · 11/16/2020 13:40
Pfizer's Upjohn spinoff completes merger with Mylan to form Viatris
Pfizer (PFE) completes the deal to spin off its Upjohn business and combine it with Mylan NV (MYL) to form Viatris (VTRS), which will start trading tomorrow under the ticker
Seekingalpha · 11/16/2020 13:00
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.
Benzinga · 11/15/2020 15:14
Is Pfizer Stock A Buy After Its Coronavirus Vaccine Proved 90% Effective?
Investor's Business Daily · 11/13/2020 20:22
The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 5)
Benzinga · 11/06/2020 12:47
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc.
Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three and nine months ended September 30, 2020.
PR Newswire · 11/06/2020 11:59
Why Mylan (MYL) Might Surprise This Earnings Season
Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 11/02/2020 13:33
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris
Mylan N.V. (NASDAQ: MYL) today announced that Bill Szablewski, CFA, has joined the company as Head of Capital Markets, in a new leadership role working closely with senior leadership. He will be serving in that same capacity for VIATRISTM ("Viatris").
PR Newswire · 11/02/2020 12:30
Will Mylan (MYL) Beat Estimates Again in Its Next Earnings Report?
Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks · 10/30/2020 17:10
Pfizer (PFE) Q3 Earnings Top, Sales Miss, View Narrowed
Pfizer (PFE) beats estimates for earnings while missing the same for sales. It narrows its financial outlook for the year.
Zacks · 10/27/2020 15:07
Were Hedge Funds Right About Souring On Mylan N.V. (MYL)?
In this article you are going to find out whether hedge funds think Mylan N.V. (NASDAQ:MYL) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]
Insider Monkey · 10/27/2020 03:45
Pfizer Inc. -- Moody's assigns P-1 rating to Pfizer's euro CP program
Moody's · 10/26/2020 19:39
Stay Away From Kodak Stock Until Its Hobby Is a Business
Kodak (NYSE:KODK) is pledging to move ahead with making Active Pharmaceutical Ingredients (APIs) for generic drugs, even though the company has not received assurances that it will obtain government funding for that business. Unfortunately for the company, investors don’t seem to be enthused about the venture; as of this writing, Kodak stock is down 17% over the last 30 days. Source: Katherine Welles / Shutterstock.com To recap, this summer Kodak submitted a “letter of interest” for a $765 million loan that would enable the company to manufacture APIs for generic drugs. Kodak stock, which was long left for dead, soared on the news. However, Kodak immediately was hit by allegations of   insider trading.InvestorPlace - Stock Market News, Stock Advice & Trading Tips But there’s a bigger problem with this narrative. As investors begin to digest the actual substance of the news, the story doesn’t get better. Kodak has institutional knowledge of chemical manufacturing. But pharmaceutical manufacturing? Not so much. And that makes me wonder if Kodak is committed to this latest venture or if it’s just a hobby that may lead to the company making an acquisition. Either way, I can’t recommend the stock, but I’ll let you decide. 7 Airline Stocks to Buy on Pelosi Stimulus Hopes Globalism Versus Nationalism To understand why the U.S. government offered Kodak this opportunity in the first place, you have to consider the current national debate between globalism and nationalism. Since the 1980s, the United States has been outsourcing American jobs to cheaper, overseas markets. As a result, the U.S. became heavily dependent on these nations for our energy, other commodities, many manufacturing goods, etc. President Donald Trump, for better or worse, took a wrecking ball to globalism. Even before the pandemic, the Trump administration had been focusing on bringing supply chains back to America. According to the nationalists, this is a matter of national security as well as a benefit to the economy. Can Kodak Make America Great Again? With that as a backdrop, the Kodak deal at least makes a smidgen of sense. For years,  generic drugs have been produced offshore. The reality is that many of the major manufacturers of U.S. generic drugs  are not wholly located in America. For example, Teva Pharmaceuticals (NYSE:TEVA) has dual headquarters in Israel and the U.S. The same is true for Mylan (NASDAQ:MYL) which has offices in the United Kingdom and the Netherlands, as well as a “global center” in Pennsylvania. From a 50,000-foot view, this seems to be the reason that Kodak was considered for this loan. Trump and White House Trade Director Peter Navarro made a point to refer to Kodak as a great American company. And the Wall Street Journal recently confirmed at least the broad outline of this line of reasoning. “Trump administration officials said the Kodak alliance would help expedite domestic production of drugs that can treat a variety of medical conditions and loosen U.S. reliance on foreign sources in countries such as China and India.” Of course, this also means that the loan will not be approved if Trump is defeated. In fact, Kodak said as much  when it unveiled its “Letter of Interest” (LOI) for the loan. To be clear, Kodak does have limited experience as a chemical manufacturer. But that doesn’t necessarily translate into the company manufacturing pharmaceuticals  on a large scale. The Bottom Line on Kodak Stock Were you one of the investors who jumped on Kodak stock at the end of July? If so, congratulations, you’re sitting on a gain of nearly 400%. And that’s why it may be time to sell the shares before you commit the cardinal sin of losing your gains. Kodak is attempting to reinvent itself by breaking into a business in which it has little experience. And it’s a field that’s well-established with several significant players, including a number in the U.S. Nevertheless, the re-election of Trump would go a long way towards ensuring that the company does receive the $765 million dollar loan. Otherwise, I don’t think there’s a good chance of this deal being  finalized. And without that funding, it appears that Kodak has a hobby, not a business. And I don’t believe in making investments based on hobbies. On the date of publication Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article. Chris Markoch is a freelance financial copywriter who has been covering the market for over six years. He has been writing for InvestorPlace since 2019. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company The post Stay Away From Kodak Stock Until Its Hobby Is a Business appeared first on InvestorPlace.
InvestorPlace · 10/23/2020 14:50
Biogen Misses on Third-Quarter Earnings and Cuts Guidance
Drugmaker Biogen's third-quarter results feel the effect of generic versions of its multiple sclerosis treatment.
TheStreet.com · 10/21/2020 14:18
Pfizer: Inexpensive Income Stock With A Corona Vaccine Kicker
Pfizer is trading at an inexpensive valuation and offers a reliable dividend with an above-average yield.The stock has some upside potential over the coming years, and combined with the dividend, total returns could be very solid.In a best-case scenario, Pfizer could be the leader in the COVID-19 vaccine race, potentially providing a big one-time boost to profits and the share price.
Seekingalpha · 10/15/2020 12:30
These stocks trading at discounts are worth considering, traders say
Matt Maley of Miller Tabak and John Petrides of Tocqueville Asset Management sift through a "Trading Nation" fire sale to find bargain buys in the market. With CNBC's Kate Rogers.
CNBC.com · 10/14/2020 18:39
Got $500? 3 Big Pharma Stocks You Can Buy Now That Pay Dividends
MotleyFool.com · 10/14/2020 08:35
Webull provides a variety of real-time MYL stock news. You can receive the latest news about Mylan NL through multiple platforms. This information may help you make smarter investment decisions.
About MYL
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The Company's Cold-EEZE family of brands includes OTC cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the United States. The North America segment primarily develops, manufactures, sells and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream or ointment form. The Europe segment sells pharmaceuticals under their International Nonproprietary Name (INN), such as active pharmaceutical ingredient (API), in certain European countries. The Rest of World segment is primarily made up of its operations in India, Australia, Japan and New Zealand.